Legend Biotech Corp

Legend Biotech Corporation is a clinical-stage biotechnology company whose core business is the development of cell therapies for cancer, most notably the CAR-T therapy CARVYKTI® (ciltacabtagene autoleucel). The company’s regulatory filings explicitly state that its product development process requires the “completion of preclinical laboratory tests and animal studies performed in accordance with the FDA's good laboratory practices (“GLP”) regulations.” Its research and development activities are fundamentally dependent on animal experimentation to demonstrate safety and efficacy before advancing to human clinical trials.

The company’s own Code of Conduct acknowledges this reliance, stating a commitment to “the ethical and humane treatment of animals in all aspects of our work, including research, product development, business partnerships and operations.” This formal policy confirms that animal testing is an integral and sanctioned component of its business model. As a biotechnology firm whose entire pipeline is built on preclinical research, Legend Biotech commissions, funds, and requires animal testing as a standard phase of development for all its therapeutic candidates.